Stockscreener 앱 받기
66.57
0.14%
0.09
시장 영업 전:
66.31
-0.26
-0.39%
전일 마감가:
$66.48
열려 있는:
$67.07
하루 거래량:
684.47K
Relative Volume:
1.13
시가총액:
$3.60B
수익:
$155.82M
순이익/손실:
$-40.42M
주가수익비율:
-93.76
EPS:
-0.71
순현금흐름:
$3.58M
1주 성능:
+2.97%
1개월 성능:
-11.87%
6개월 성능:
+6.41%
1년 성능:
+20.45%
1일 변동 폭
$65.75
$67.80
1주일 범위
$63.62
$68.24
52주 변동 폭
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
ACLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
66.57 | 3.60B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha
Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia
Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat
Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India
(ACLX)Analyzing Arcellx's Short Interest - Benzinga
Oversold Conditions For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat
Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia
arcellx CEO Elghandour sells stock worth $2.26 million By Investing.com - Investing.com Nigeria
Arcellx CFO Michelle Gilson sells shares worth $700,959 By Investing.com - Investing.com Australia
arcellx CEO Elghandour sells stock worth $2.26 million - Investing.com
Arcellx CFO Michelle Gilson sells shares worth $700,959 - Investing.com India
Arcellx Breaks Below 200-Day Moving AverageNotable for ACLX - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Arcellx's chief medical officer sells shares worth $498,795 By Investing.com - Investing.com Australia
Arcellx CFO Michelle Gilson sells $831,378 in stock By Investing.com - Investing.com Nigeria
Principal Financial Group Inc. Has $336,000 Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx CEO Rami Elghandour sells shares worth $2.24 million By Investing.com - Investing.com Australia
Arcellx chief medical officer sells shares worth $498,795 By Investing.com - Investing.com Canada
Arcellx chief medical officer sells shares worth $498,795 - Investing.com
Christopher Heery Sells 3,061 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Christopher Heery Sells 3,301 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Arcellx CEO Rami Elghandour sells shares worth $2.24 million - Investing.com
Arcellx CFO Michelle Gilson sells $831,378 in stock - Investing.com India
Arcellx (NASDAQ:ACLX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Receives $105.93 Consensus Price Target from Analysts - MarketBeat
Viking stock among buyout targets: Oppenheimer (VKTX:NASDAQ) - Seeking Alpha
(ACLX) On The My Stocks Page - Stock Traders Daily
Arcellx Stock Earns 82 Relative Strength Rating - Yahoo! Voices
arcellx director Kavita Patel sells shares worth $115,450 - Investing.com India
arcellx director Kavita Patel sells shares worth $115,450 By Investing.com - Investing.com Nigeria
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):